Rhythm Pharmaceuticals, Inc. (BMV:RYTM)
Mexico
· Delayed Price · Currency is MXN 1,866.76
-158.24 (-7.81%)
At close: Nov 18, 2025
Rhythm Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 189.76 | 130.13 | 77.43 | 23.64 | 3.15 | Upgrade
|
| Revenue Growth (YoY) | 45.83% | 68.06% | 227.56% | 649.46% | - | Upgrade
|
| Cost of Revenue | 19.49 | 13.37 | 9.3 | 2.13 | 0.6 | Upgrade
|
| Gross Profit | 170.27 | 116.76 | 68.13 | 21.51 | 2.56 | Upgrade
|
| Selling, General & Admin | 194.94 | 144.3 | 117.53 | 92.03 | 68.49 | Upgrade
|
| Research & Development | 167.34 | 145.56 | 134.95 | 108.63 | 104.13 | Upgrade
|
| Operating Expenses | 362.28 | 289.86 | 252.48 | 200.66 | 172.61 | Upgrade
|
| Operating Income | -192.02 | -173.1 | -184.36 | -179.16 | -170.06 | Upgrade
|
| Interest Expense | -20.58 | -20.6 | -13.89 | -5.2 | - | Upgrade
|
| Interest & Investment Income | 15.29 | 14.71 | 13.95 | 4.03 | 0.45 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.26 | 2.24 | 0.19 | 0.25 | 100 | Upgrade
|
| EBT Excluding Unusual Items | -196.04 | -176.76 | -184.11 | -180.08 | -69.61 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | -1.04 | - | Upgrade
|
| Other Unusual Items | - | 8.9 | - | - | - | Upgrade
|
| Pretax Income | -196.04 | -260.26 | -184.11 | -181.12 | -69.61 | Upgrade
|
| Income Tax Expense | 0.5 | 0.35 | 0.56 | - | - | Upgrade
|
| Net Income | -196.54 | -260.6 | -184.68 | -181.12 | -69.61 | Upgrade
|
| Preferred Dividends & Other Adjustments | 5.38 | 3.97 | - | - | - | Upgrade
|
| Net Income to Common | -201.92 | -264.57 | -184.68 | -181.12 | -69.61 | Upgrade
|
| Shares Outstanding (Basic) | 65 | 61 | 58 | 52 | 50 | Upgrade
|
| Shares Outstanding (Diluted) | 65 | 61 | 58 | 52 | 50 | Upgrade
|
| Shares Change (YoY) | 6.54% | 5.76% | 10.65% | 5.08% | 12.40% | Upgrade
|
| EPS (Basic) | -3.11 | -4.34 | -3.20 | -3.47 | -1.40 | Upgrade
|
| EPS (Diluted) | -3.11 | -4.34 | -3.20 | -3.47 | -1.40 | Upgrade
|
| Free Cash Flow | -116.63 | -113.88 | -136.2 | -173.71 | -146.44 | Upgrade
|
| Free Cash Flow Per Share | -1.79 | -1.87 | -2.36 | -3.33 | -2.95 | Upgrade
|
| Gross Margin | 89.73% | 89.73% | 87.99% | 90.98% | 81.01% | Upgrade
|
| Operating Margin | -101.19% | -133.03% | -238.10% | -757.92% | -5391.85% | Upgrade
|
| Profit Margin | -106.41% | -203.32% | -238.52% | -766.22% | -2207.10% | Upgrade
|
| Free Cash Flow Margin | -61.46% | -87.51% | -175.91% | -734.87% | -4642.90% | Upgrade
|
| EBITDA | -190.68 | -171.54 | -182.6 | -177.49 | -168.9 | Upgrade
|
| EBITDA Margin | -100.48% | -131.83% | -235.83% | - | - | Upgrade
|
| D&A For EBITDA | 1.34 | 1.56 | 1.76 | 1.67 | 1.16 | Upgrade
|
| EBIT | -192.02 | -173.1 | -184.36 | -179.16 | -170.06 | Upgrade
|
| EBIT Margin | -101.19% | -133.03% | -238.10% | - | - | Upgrade
|
| Revenue as Reported | 189.76 | 130.13 | 77.43 | 23.64 | 3.15 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.